In conclusion, in mouse models, our compelling results show that CCR3 is therefore a major determinant of prostate cancer progression by influencing tumour size and adipose tissue remodelling and that its effect is substantially influenced by obesity. This evidence concerns the gene CCR3 and obesity due to melanocortin 4 receptor deficiency.